Abstract

This is the first in a series of preliminary assessments of new medicines, to be published about four times a year. We hope they will help prescribers decide what place the new product could have in their treatment plan or drug formulary. The comments are based upon our own appraisal of the work cited by the manufacturers, and the views of relevant specialists. We may review some of the drugs in more detail later. In this issue we discuss four products introduced at the end of last year.